BioCardia, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
BioCardia, Inc. (BCDA) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $1.80 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-04-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2020-04-09
- BioCardia, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2017 was $1.80M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|
| 2017-12-31 | $1.80M 10-K · filed 2020-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |